.svg)
For decades, clinical trial technology has evolved alongside a growing list of acronyms — IVRS, IWRS, IXRS, IRT, and RTSM. While these terms reflect meaningful shifts in how trials are managed, they’ve also lingered longer than the technologies they describe.
At Endpoint Clinical, we haven’t just followed this evolution — we’ve helped shape it. With a fifth-generation RTSM platform built on the pillars of quality, speed, and agility, we’re defining what comes next.
These terms mark technological progress — but they also persist across search behavior, regulatory documents, and sponsor language.
Legacy acronyms still appear in protocols, study documentation, and RFPs. Study teams often search for “IWRS” or “IXRS” when vetting vendors. Rather than abandoning these terms, we meet teams where they are — while helping them adopt systems that reflect what trials need today.
Built for the Future: Quality, Speed, and Agility by Design
As clinical trials grow more complex, sponsors and CROs are being asked to do the impossible: launch faster, manage more moving parts, and adapt to shifting protocols — all without compromising quality. Many RTSM systems claim to support that kind of flexibility. But for most study teams, that support still comes with trade-offs: longer timelines, brittle mid-study updates, or platform limitations that force operational workarounds.
That’s why we took everything we’ve learned over the past 15 years supporting more than 2,000 global trials — and built something that goes further.
Elosity isn’t just another generation of RTSM. It’s a platform designed to make RTSM work for you. To remove friction. To handle complexity without adding it. And to support the way trials operate now — not the way systems were built to function a decade ago.
It’s built on three core pillars: quality, speed, and agility. Not as buzzwords — but as the measurable, day-to-day impact that today’s sponsors and CROs need.
For most sponsors and CROs, quality issues don’t come from dramatic system failures — they come from the small things: inconsistencies across sites, misaligned data between platforms, or manual workarounds that introduce risk. And too often, RTSM is treated as a standalone tool rather than a core part of the ecosystem.
Elosity changes that. It was designed to operate as part of a connected, end-to-end trial environment — integrating cleanly with systems like EDC, CTMS, and eConsent. That connectivity helps reduce errors before they happen and gives teams a more complete view of what’s really going on in their studies.
But integration alone isn’t enough. That’s why Elosity also includes automated quality gates built directly into the system — checkpoints that flag potential issues early, like configuration mismatches or gaps in logic tied to protocol requirements. Instead of relying on manual reviews to catch these late in the game, the platform helps surface them up front, before they can slow things down or cause rework later.
It’s not just about passing UAT. It’s about preventing issues before they happen — and making quality something your team doesn’t have to chase down.
Everyone wants to launch faster. But speed without control is a liability. That’s why Elosity is built to accelerate timelines without skipping steps. Sponsors can launch studies in as little as 2–4 weeks — not by cutting corners, but by rethinking the build process itself.
Reusable configurations, collaborative build reviews, and real-time visibility replace the slow, linear workflows that most teams are used to. You don’t have to wait weeks to see a working system. You don’t have to chase down status updates. And you don’t have to pause progress every time a protocol shift comes in.
The result? Less lag between decision and deployment — and more confidence that your trial is moving in the right direction.
Trial designs rarely stay static. Whether it’s a new cohort, a dosing change, or an unplanned country rollout, study teams need systems that can flex as fast as their protocols. Unfortunately, many RTSM platforms make mid-study changes feel like mini rebuilds — slow, risky, and expensive.
Elosity was built to make those changes routine. Its modular architecture allows updates to be made in real time, with minimal disruption and no unnecessary rework. Sponsors and CROs can implement changes without triggering a full regression test or restarting timelines from scratch.
It’s not just about being ready for change. It’s about being able to respond to it — quickly, confidently, and without losing momentum.
There’s no shortage of buzzwords in clinical tech — but when the pressure is real and the stakes are high, study teams don’t need noise. They need systems that work. That flex. That accelerate, instead of complicate.
That’s what modern RTSM should deliver. And that’s what Elosity was built to do.
By combining 15 years of operational experience with a fifth-generation platform, Endpoint Clinical is helping sponsors and CROs move faster, manage complexity with less friction, and maintain the quality that regulators — and patients — expect.
Because the next wave of trials won’t be defined by who has the most tools — but by who can use them the most effectively.
Explore what Elosity can do for you. Request a demo today.
Minimize risk when adopting eClinical tech to support decentralized clinical trials (DCTs).
Why RTSM data integrity matters more than ever in today’s complex, fast-moving clinical trials.
Clinical trial acronyms have evolved—so has the tech. Discover what’s next!
